Clinical Medicine Insights: Oncology 2011:5 325-332
Published on 20 Oct 2011
Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Oncology
Therapeutic advances changed dramatically in 2010 with the U.S. FDA approval of the autologous cellular immunotherapy sipuleucel-T for the treatment of men with asymptomatic or minimally symptomatic metastatic CRPC. This is an updated review on the data regarding therapeutic options with particular focus on the emerging strategies for incorporating sipuleucel-T into this changing landscape.
Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population.
PDF (510.04 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
I had a great experience publishing our paper in Clinical Medicine Insights: Oncology. The review was prompt and fair and once it was accepted with the revisions, the editorial office was very clear and helpful with updates on the progress at each step of the publication process. I had prompt email responses to my questions. I will definitely try to publish more papers in this journal in the future. Keep the good work. ...
Facebook Google+ Twitter
Pinterest Tumblr YouTube